Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks at the Time of First Vaccination.
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2018
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 14 Jan 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 14 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.